VX-680

MK-0457 · Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VX-680, covering 2015-08-26 to 2015-08-26. Get the full timeline:

Most recent: Clinical Trial Update: A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002) [Phase 1]